Gene therapy for severe combined immunodeficiencies and beyond

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Severe combined immunodeficiency (SCID) encompasses genetic disorders impairing T cell function.
• Ex vivo gene therapy has emerged as a potential treatment for SCID.
• Natural gene correction observed in SCID patients provided a therapeutic rationale.

Purpose of the Study:

• To review the advancements in ex vivo gene therapy for SCID.
• To discuss the evolution of gene therapy vectors and safety considerations.
• To explore future directions in SCID treatment, including genome editing.

Main Methods:

• Retroviral vector-mediated gene transfer into hematopoietic stem cells.
• Analysis of gene therapy outcomes in SCID X1 and adenosine deaminase deficiency.
• Utilizing lentiviral vectors for gene transfer in Wiskott-Aldrich syndrome.

Main Results:

• Early gene therapy attempts for SCID X1 faced challenges with insertional mutagenesis leading to leukemia.
• Modifications to viral vectors, replacing enhancers with promoters, improved safety and efficacy.
• Successful generation of diverse T cell repertoires from limited progenitor cells was achieved.
• Lentiviral vectors demonstrated success in treating Wiskott-Aldrich syndrome.

Conclusions:

• Ex vivo gene therapy has evolved to become a safer and effective treatment for specific SCID types.
• Lentiviral vectors represent a significant advancement in gene transfer technology for immunodeficiencies.
• Genome editing presents a promising alternative strategy for treating SCID diseases in the future.